Inmune Bio Inc. · NASDAQ:INMB
Inmune Bio — Investor Presentation (February 2025)
21 slides from Inmune Bio's investor presentation, Feb 10, 2025
Slide 1: RDEB – An Ultra-Rare Genetic Disease with Significant Unmet Need
1 RDEB – An Ultra - Rare Genetic Disease with Significant Unmet Need *Recessive Dystrophic Epidermolysis Bullosa (RDEB) • RDEB is a severe form of epidermolysis bullosa (EB), a rare disease that causes severe skin fragility, itch and chronic pain • Children with RDEB have skin that is damaged by eve
Slide 2: Trial Summary - CORDStrom
Trial Summary - CORDStrom Investigational disease - modifying treatment for recessive dystrophic epidermolysis bullosa (RDEB) FDA = Food and Drug Administration; GOSH = Great Ormond Street Hospital; NIHR = National Institute for Health and Care Resear ch; ODD = Orphan Drug Designation; PRV = Priorit
Slide 3: CORDStrom Next Steps and Milestones
3 CORDStrom Next Steps and Milestones Productive conversations with FDA over the last few months have established a clear path forward BLA = Biologics License Application; EMA = European Medicines Agency; FDA = Food and Drug Administration; GOSH = Great Ormond St reet Hospital; IND = Investigational
Slide 4: Introduction to CORDStrom platform
Introduction to CORDStrom platform …. The most advanced mesenchymal stem/stromal cell product for clinical development
Slide 5: History of MSC developments
History of MSC developments • 1966 - “mesenchymal stem cells” discovered in adult bone marrow • 1993 – Osiris Therapeutics founded • 2001 - 3 – MSCs become DRUGS in EU and US • 2005 - Not “stem” cells but “stromal” cells • 2008 - Le Blanc Lancet paper FIRST demonstration of proven therapeutic use –
Slide 6: problems
Why such a dismal success rate? 4 primary problems
Slide 7: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc
Slide 8: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA
Slide 9: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • MSC heterogeneity – Donor - to - donor – Source -
Slide 10: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 11: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 12: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 13: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 14: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 15: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 16: problems
Why such a dismal success rate? 4 primary problems • MSC source – Bone marrow – Adipose tissue – Umbilical cord tissue – Wharton’s Jelly – Placenta – Etc etc • MSC identity – CD73/90/105 – Lots of subsets with largely unknown potency – Lack of MoA • Clinically naive – “all MSC are the same” – No nee
Slide 17: What is CORDStrom?
What is CORDStrom ? • Pooled, allogeneic umbilical cord derived MSC product available Off - The - Shelf • Benefits – – Extremely reproducible – Can be tuned for different potencies for different indications (donor mix and CPD related) with different potency assays – Extremely scaleable in existing b
Slide 18: Why is CORDStrom so good?
Why is CORDStrom so good? CORDStro m P4C CORDStro m P4B CORDStro m P4A UC VEGF secreti on 0.00 0.00 0.00 UC - 1 0.00 0.00 UC - 2 99.06 513.24 UC - 3 0.00 0.00 UC - 4 0.00 0.00 UC - 5 152.32 110.79 188.75 UC - 6 0.00 0.00 0.00 UC - 7 159.33 44.63 270.50 UC - 8 351.38 241.33 152.42 Predicted CORDStrom
Slide 19: CORDStrom Production
CORDStrom Production • CORDStrom EB will be CPD25 - 30 • 4UC pooled per batch of WCS • 1 WCS pool = 80 million annual treatments • 12500 EB cases in US • 3500 DEB cases in US • 1 optimized WCS pool will treat US EB patients for 6000 years 0 10 20 30 40 10 0 10 5 10 10 10 15 10 20 CORDStrom productiv
Slide 20: Summary
Summary • CORDStrom is a revolutionary MSC drug – Patent and manufacturing IP owned by INMB – Grown out of Pro. Mark Lowdell lab leveraging INKmune Staff and Equipment – Reproducible – Tuneable – Highly cost effective – Manufactured at scale – Established MsOA & potency assays • CORDStrom truly Off
Slide 21: Questions & Answers
21 Questions & Answers Thank you Q&A instructions